ReviewCurrent pharmaceutical design2024
The Regulation of Selenoproteins in Diabetes: A New Way to Treat Diabetes.
Review in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Effect of SGLT-2 inhibitors on COPD exacerbations in individuals with type 2 diabetes: A meta-analysis and Bayesian sensitivity analysis.Journal of diabetes investigation · 2025Pooled it
- Polyethylene Glycol Loxenatide Selectively Reduces Adiposity While Preserving Lean Body Mass in Type 2 Diabetes: A 12-Week Clinical Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Trial
- Microbiome-metabolite signaling drives aluminum stress alleviation in soybean under intercropping and selenium nanoparticle application.Plant signaling & behavior · 2026Article
- Efficacy and safety of SGLT2 inhibitors in elderly patients with type 2 diabetes.Annals of medicine · 2026Article
- Plasma 4-Hydroxyproline Levels Are Associated with Diabetes in Chinese Adults: A Cross-Sectional Analysis.Metabolites · 2026Article
- Joint association of body roundness index and HOMA-IR with risk of MASLD in Korean populations.BMC endocrine disorders · 2026Article
- Article
- Diphenylpiperazine attached to different triazole acetamide derivatives as a potent α-glucosidase inhibitor, new insight into the in silico study of an uncompetitive inhibitor.Journal of computer-aided molecular design · 2026Article
- BHMT Protects Against Diabetic Cataracts by Reducing Homocysteine and Counteracting Endoplasmic Reticulum Stress in Lens Epithelial Cells.Applied biochemistry and biotechnology · 2026Article
- Integrative analysis of placental metabolic reprogramming and microbiome alterations in gestational diabetes mellitus (GDM).Acta diabetologica · 2026Review
- Article
- Trehalose: A Promising Therapeutic Agent for Diverse Pathological Conditions.Current medical science · 2026Review
- Calebin A mitigates oxidative stress and inflammation in diabetic nephropathy via Nrf2/HO-1 and NF-κB signaling pathways.Journal of diabetes investigation · 2026Article
- Probing Combined Experimental and Computational Profiling to IdentifyMolecules (Basel, Switzerland) · 2026Article
- Quantum denoising autoencoder improves retinal fundus image quality for early diabetic retinopathy screening.Scientific reports · 2026Article
- The Potential Role of SGLT2 Inhibitors in the Treatment of Depression: Mechanisms and Clinical Prospects.Drug design, development and therapy · 2026Review
- Three-dimensional bioprinted hydrogels for the management of diabetic wounds: A review.BioImpacts : BI · 2026Review
- Discovery of Novel 1,3,4-oxadiazole-based Inhibitors Against Urease and Diabetes: Design, Synthesis, SAR, Biological, and Molecular Docking Screening.Medicinal chemistry (Shariqah (United Arab Emirates)) · 2026Article
- The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes.Frontiers in oncology · 2026Article
- Interpretable glucose forecasting for type 2 diabetes across traditional, deep, and large language models.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Selenium is an essential micronutrient required for the synthesis and function of selenoproteins, most of which are enzymes involved in maintaining oxidative balance in the body. Diabetes is a group of metabolic disorders characterized by high blood glucose levels over a prolonged period of time. There are three main types of diabetes: type 1, type 2, and gestational diabetes. This review summarizes recent advances in the field of diabetes research with an emphasis on the roles of selenoproteins on metabolic disturbance in diabetes. We also discuss the interaction between selenoproteins and glucose and lipid metabolism to provide new insights into the prevention and treatment of diabetes.
Indexed as
Identifiers
38706350What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.